Please use this identifier to cite or link to this item:
Title: Revisiting loxapine: a systematic review
Author: Popovic, Dina
Philippe, Nuss
Vieta i Pascual, Eduard, 1963-
Keywords: Antipsicòtics
Trastorn bipolar
Antipsychotic drugs
Manic-depressive illness
Issue Date: 1-Apr-2015
Publisher: BioMed Central
Abstract: Loxapine is an antipsychotic used in psychiatry for over 40 years with a well-established profile. Loxapine is a dibenzoxazepine tricyclic antipsychotic agent, available for oral, intramuscular and inhalatory administration. In the light of the recent approval by the regulatory agencies of inhaled loxapine for use in the acute treatment of mild-to-moderate agitation in adults affected with schizophrenia or bipolar disorder, this article aims to critically review the available literature on loxapine, irrespective of its formulation. This review examines the efficacy and tolerability of the various formulations of loxapine in the treatment of agitation and aggression in patients affected with schizophrenia, bipolar disorder and other psychiatric conditions. A comprehensive and systematic literature search of PubMed/MEDLINE was conducted, and relevant pharmacodynamic and pharmacokinetic data was included. The findings from the literature were critically reviewed and synthesized. The available data suggests that the antipsychotic efficacy of loxapine is similar to the efficacy of other typical or atypical antipsychotics, with an adverse effects profile comparable to that of the typical antipsychotics at high doses for chronic treatment. As an acute treatment in agitation associated with schizophrenia or bipolar disorder, inhaled loxapine was developed as an innovative and rapid option which appears to be efficacious and tolerable.
Note: Reproducció del document publicat a:
It is part of: Annals of General Psychiatry, 2015, vol. 14, num. 15, p. 1-8
Related resource:
ISSN: 1744-859X
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
651753.pdf542.23 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons